北京、上海、广州、天津、杭州、成都六城市α-葡萄糖苷酶抑制剂使用情况比较

摘要

Objective To analyze and compare utilization of α-glucosidase inhibitors in Beijing, Shanghai, Guangzhou, Tianjin, Hangzhou, and Chengdu. Methods It was summarized in the article name, specification, number of prescrip-tion, dispensary quantity and amount of Acarbose, Voglibose, and Miglitol. Results Respectively in Beijing, Shanghai, Guangzhou, Tianjin, Hangzhou and Chengdu, DDDs of Acarbose were 1 561 598.00, 444 800.17, 368 790.33, 624 876.00, 183 533.67, and 111 732.17; DDC of Acarbose were 14.56, 14.18, 13.88, 14.09, 13.58, and 13.49; DDDs of Voglibose were 40 393.83, 80 826.67, 70 604.17, 107 670.67, 28 642.50, and 270.00; DDC of Voglibose were 13.44, 12.80, 13.07, 13.28, 12.41, and 12.12. While in Shanghai and Chengdu DDDs of Miglitol were 36.00 and 29 170.00; DDC of Miglitol were 18.54 and 14.10. Conclusion Low DDC reveals superior economics properties on all three kinds of drugs. Acarbose and Voglibose are more frequently used in Beijing, Shanghai, Guangzhou, Tianjin, Hangzhou; while Acarbose and Miglitol more frequently in Chengdu, which suggests a large market ofα-glucosidase inhibitors in metropolis.%目的：分析并比较北京、上海、广州、天津、杭州、成都六城市α-葡萄糖苷酶抑制剂的处方情况。方法对这六个城市的阿卡波糖、伏格列波糖、米格列醇三种药品的口服剂型的药品名称、规格、处方张数、取药数量、取药金额进行统计分析。结果阿卡波糖在北京、上海、广州、天津、杭州和成都的 DDDs分别为1561598.00、444800.17、368790.33、624876.00、183533.67、111732.17，DDC分别为14.56、14.18、13.88、14.09、13.58、13.49；伏格列波糖在北京、上海、广州、天津、杭州、成都的DDDs分别为40393.83、80826.67、70604.17、107670.67、28642.50、270.00，DDC分别为13.44、12.80、13.07、13.28、12.41、12.12；米格列醇在上海、成都的DDDs分别为36.00、29170.00，DDC分别为18.54、14.10。结论这些药物的DDC均较小，具有较好的经济学属性。北京、上海、广州、天津、杭州以阿卡波糖和伏格列波糖为主，成都地区以阿卡波糖和米格列醇为主。国内一线城市α-葡萄糖苷酶抑制剂市场很大。